Dr.Shweta Singh

Dr. Obuli N. Ramachandran, Dr.Avnindra Gupta, Dr.Lalit Verma, Dr.Anuja Patil

Abstract

Purpose- To evaluate safety and efficacy of ranibizumab biosimilar ( Oceva) for the treatment of chorioretinal diseases( DME, CNVM, RVO)
Method- A single centre, retrospective analysis of the data of patients who have received intravitreal injection oceva at our centre from July 2022 to March 2023. The outcome measures were changes in corrected distance visual acuity(CDVA) and central foveal thickness(CFT) from baseline to 1 month follow-up
Result- Thirteen eyes of 12 patients who received intravitreal injection Oceva were included. The indications for injection included DME in 6 patients, CNVM in 3 patients and RVO in 3 patients. The mean Log MAR CDVA improved from 0.68 to 0.61 from baseline to 1 month follow up. There was decrease in mean CFT from 404.52um to 261.29um from baseline to 1month follow-up. No ocular or systemic adverse events noted
Conclusion- Oceva showed rapid improvement in CDVA and CFT in most of the eyes at 1month follow up